Submit a comment
Citation Information: J Clin Invest. 1979;64(1):333-336. https://doi.org/10.1172/JCI109458.
Abstract
The ability of antipili antibody to prevent ascending urinary tract infection was investigated in rats. One group of rats was immunized passively with rabbit antisera to purified pili and challenged by intravesicular inoculation of 5 x 10(7) heavily piliated Escherichia coli. Only 2 of 14 immunized animals developed cortical abscesses as compared to 13 of 15 control rats given normal rabbit serum (P equals 0.0001). The mean log titer of bacteria in the kidneys of the immunized rats was 0.85 vs. 6.08 in the controls (P less than 0.005). A second group was actively immunized with pili. 3 of 16 immunized animals became infected as compared to 10 of 15 controls (P equals 0.01). The mean log titers were 2.13 and 4.54, respectively (P less than 0.01). A third group was passively immunized and challenged with a strain that had different O, K, and H antigens but shared pili antigens. Abscesses occurred in 4 of 15 immunized animals as compared to 13 of 15 controls (P equals 0.001). The mean log titers were 2.37 and 5.63, respectively (P less than 0.005). These results indicate that antipili antibody protects rats against ascending urinary tract infections.
Authors
F J Silverblatt, L S Cohen
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)